To better quantify the impact of AHD - defined in this study as people with CD4 counts ≤200 cells/mm3 - and support evidence-based policy, resource allocation, and research prioritisation, population-level mortality estimates are needed. The gene discussed is CD4; the disease is mitochondrial DNA depletion syndrome 4a.